{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:30:06Z","timestamp":1793896206188,"version":"4.8.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41409-025-02786-w","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:12:50Z","timestamp":1766747570000},"page":"352-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-6598","authenticated-orcid":false,"given":"Robert","family":"Puckrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Sapon-Cousineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-339X","authenticated-orcid":false,"given":"Anthea","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shafey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"2786_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363.","journal-title":"Blood"},{"key":"2786_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/bjh.18519","volume":"202","author":"G Hess","year":"2023","unstructured":"Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, et al. Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol. 2023;202:749\u201359.","journal-title":"Br J Haematol"},{"key":"2786_CR3","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2022;41:JCO2102370.","DOI":"10.1200\/JCO.21.02370"},{"key":"2786_CR4","doi-asserted-by":"crossref","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41:2594\u2013606.","DOI":"10.1200\/JCO.22.01797"},{"key":"2786_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.87","volume":"8","author":"MA O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly MA, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis. Hemasphere. 2024;8:e87.","journal-title":"Hemasphere"},{"key":"2786_CR6","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ajh.27056","volume":"98","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023;98:1699\u2013710.","journal-title":"Am J Hematol"},{"key":"2786_CR7","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","volume":"6","author":"G Iacoboni","year":"2022","unstructured":"Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6:3606\u201310.","journal-title":"Blood Adv"},{"key":"2786_CR8","doi-asserted-by":"crossref","unstructured":"Ahmed N, Thiruvengadam S, Hamadani M, Hu ZH, Grover NS, Shadman M, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025;9:5382\u201396.","DOI":"10.1182\/bloodadvances.2024015014"},{"key":"2786_CR9","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene Maraleucel in Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2024;42:1146\u201357.","journal-title":"J Clin Oncol"},{"key":"2786_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.23.02470","volume":"43","author":"TJ Phillips","year":"2025","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trn\u011bn\u00fd M, et al. Glofitamab in Relapsed\/Refractory Mantle Cell Lymphoma: Results From a Phase I\/II Study. J Clin Oncol. 2025;43:318\u201328.","journal-title":"J Clin Oncol"},{"key":"2786_CR11","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023;41:3988\u201397.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02786-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:56:01Z","timestamp":1772808961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02786-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2786"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02786-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not receive funding from any source. RP has received honoraria from Abbvie, Astrazeneca, Beigene, Eli Lilly, Incyte, Kite, Janssen, Pfizer, Roche, and Seagen. VSC has received honoraria from Kite. AP has received honoraria from Abbvie, Astrazeneca, Beigene, Eli Lilly, Incyte, Kite, Janssen, Roche, and Seagen. MS has received honoraria from Abbvie, AstraZeneca, Beigene, Eli Lilly, Incyte, Kite, Janssen, and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}